No­var­tis hands off 3 pre­clin­i­cal pro­grams to the an­tivi­ral R&D mas­ters at Gilead

Gilead CEO Daniel O’Day’s new task hunt­ing up a CSO for the com­pa­ny isn’t stop­ping the in­dus­try’s dom­i­nant an­tivi­ral play­er from do­ing pipeline deals.

The big biotech to­day snapped up 3 pre­clin­i­cal an­tivi­ral pro­grams from phar­ma gi­ant No­var­tis, with drugs promis­ing to treat hu­man rhi­novirus, in­fluen­za and her­pes virus­es. We don’t know what the up­front is, but the back end has $291 mil­lion in mile­stones baked in.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER